2-[1-[[5-chloro-6-(propan-2-ylamino)pyrimidine-4-carbonyl]amino]ethyl]-N-[5-chloro-4-(trifluoromethyl)pyridin-2-yl]-1,3-thiazole-5-carboxamide | 1096707-57-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-[1-[[5-chloro-6-(propan-2-ylamino)pyrimidine-4-carbonyl]amino]ethyl]-N-[5-chloro-4-(trifluoromethyl)pyridin-2-yl]-1,3-thiazole-5-carboxamide
• CAS: 1096707-57-1
• 化学式: C₂₀H₁₈Cl₂F₃N₇O₂S
• 分子量: 548.376
• InChiKey: OGDBWHVEACLPCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  150
• 氢给体数：
  3
• 氢受体数：
  11

文献信息

• COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
  申请人：Chen Weirong

  公开号：US20090036419A1

  公开（公告）日：2009-02-05

  The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

  本发明提供了作为Raf蛋白激酶抑制剂有用的化合物。本发明还提供了这些化合物的组合物，以及治疗Raf介导疾病的方法。
• [EN] CONJUGATE COMPOUNDS FOR THE DEGRADATION OF RAF<br/>[FR] COMPOSÉS CONJUGUÉS POUR LA DÉGRADATION DE RAF
  申请人：ZAMBONI CHEM SOLUTIONS INC

  公开号：WO2020168172A1

  公开（公告）日：2020-08-20

  The present disclosure provides, inter alia, RAF-Degrading Conjugate Compounds that are useful in the treatment of cancer and other RAF related diseases. Also provided are, pharmaceutical compositions, methods of treatment, and kits comprising a RAF-Degrading Conjugate Compound.

  本公开提供了用于治疗癌症和其他与RAF相关疾病的RAF降解共轭化合物。还提供了药物组合物、治疗方法和包含RAF降解共轭化合物的试剂盒。
• PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
  申请人：Sunesis Pharmaceuticals, Inc.

  公开号：EP2167489B1

  公开（公告）日：2017-05-03
• THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS
  申请人：Sunesis Pharmaceuticals, Inc.

  公开号：EP3231798B1

  公开（公告）日：2019-10-09
• Compounds Useful as Raf Kinase Inhibitors
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20170158686A1

  公开（公告）日：2017-06-08

  The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.